心脏型脂肪酸结合蛋白、神经丝轻链、白介素-10和S100钙结合蛋白B在创伤性脑损伤急性诊断与严重程度评估中的潜力
该研究于2011-2013年在芬兰Turku大学医院前瞻性纳入≥18岁任何严重程度TBI且具备CT扫描指征的患者及骨科损伤对照,按GCS 13-15、9-12、3-8分为轻型、中型、重型TBI,入院24小时内采集血清以高性能试剂盒检测S100B、H-FABP、NF-L、IL-10。共纳入189例患者,NF-L检测175例TBI和40例对照,其余三项标志物检测184例TBI和39例对照。各标志物在不同严重程度分级间差异有统计学意义,但均不能区分中型与重型TBI;从急诊出院的mTBI患者IL-10、H-FABP、NF-L水平低于收入神经外科病房者;各标志物单独或联合均不能区分CT阳性(n=36)或CT阴性(n=58)的mTBI患者与对照。结论提示这些标志物不能单独用于急性创伤患者mTBI的诊断。
要点
- 各标志物在轻型、中型、重型TBI分级间差异均有统计学意义,但无一能区分中型与重型TBI。
- 急诊出院的mTBI患者IL-10为0.26(IQR=0.21, 0.39)pg/mL、H-FABP为4.15(IQR=2.72, 5.83)ng/mL、NF-L为8.6(IQR=6.35, 15.98)pg/mL,均低于收入神经外科病房者。
- 收入神经外科病房的mTBI患者IL-10为0.55(IQR=0.31, 1.42)pg/mL、H-FABP为6.022(IQR=4.19, 20.72)ng/mL、NF-L为13.95(IQR=8.33, 19.93)pg/mL。
- 较年长的mTBI患者H-FABP和NF-L水平更高。
- 各标志物单独或联合均不能区分CT阳性(n=36)或CT阴性(n=58)的mTBI患者与骨科对照。
适用人群与场景
- 年龄≥18岁、任何严重程度且具备CT扫描指征的TBI患者,以及骨科损伤对照,2011-2013年于芬兰Turku大学医院前瞻性招募。
诊断标准与关键阈值
- 按GCS分级:GCS 13-15为轻型TBI(mTBI),GCS 9-12为中型TBI(moTBI),GCS 3-8为重型TBI(sTBI)。
- 血清样本于入院24小时内采集,以高性能试剂盒检测标志物水平。
研究设计与关键结果
- 前瞻性纳入189例患者,NF-L检测175例TBI和40例对照,S100B、H-FABP、IL-10检测184例TBI和39例对照。
- 各标志物在不同严重程度分级间差异有统计学意义,但无一能区分moTBI与sTBI。
- 急诊出院的mTBI患者IL-10为0.26(IQR=0.21, 0.39)pg/mL、H-FABP为4.15(IQR=2.72, 5.83)ng/mL、NF-L为8.6(IQR=6.35, 15.98)pg/mL,低于收入神经外科病房者的IL-10 0.55(IQR=0.31, 1.42)pg/mL、H-FABP 6.022(IQR=4.19, 20.72)ng/mL、NF-L 13.95(IQR=8.33, 19.93)pg/mL。
- 较年长的mTBI患者H-FABP和NF-L水平更高。
- 各标志物单独或联合均不能区分CT阳性(n=36)或CT阴性(n=58)的mTBI患者与骨科对照。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为这些标志物不能单独用于急性创伤患者mTBI的诊断。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: There is substantial interest in blood biomarkers as fast and objective diagnostic tools for traumatic brain injury (TBI) in the acute setting.
METHODS: Adult patients (≥18) with TBI of any severity and indications for CT scanning and orthopaedic injury controls were prospectively recruited during 2011-2013 at Turku University Hospital, Finland. The severity of TBI was classified with GCS: GCS 13-15 was classified as mild (mTBI); GCS 9-12 as moderate (moTBI) and GCS 3-8 as severe (sTBI). Serum samples were collected within 24 hours of admission and biomarker levels analysed with high-performance kits. The ability of biomarkers to distinguish between severity of TBI and CT-positive and CT-negative patients was assessed.
RESULTS: Among 189 patients recruited, neurofilament light (NF-L) was obtained from 175 patients with TBI and 40 controls. S100 calcium-binding protein B (S100B), heart fatty-acid binding protein (H-FABP) and interleukin-10 (IL-10) were analysed for 184 patients with TBI and 39 controls. There were statistically significant differences between levels of all biomarkers between the severity classes, but none of the biomarkers distinguished patients with moTBI from patients with sTBI. Patients with mTBI discharged from the ED had lower levels of IL-10 (0.26, IQR=0.21, 0.39 pg/mL), H-FABP (4.15, IQR=2.72, 5.83 ng/mL) and NF-L (8.6, IQR=6.35, 15.98 pg/mL) compared with those admitted to the neurosurgical ward, IL-10 (0.55, IQR=0.31, 1.42 pg/mL), H-FABP (6.022, IQR=4.19, 20.72 ng/mL) and NF-L (13.95, IQR=8.33, 19.93 pg/mL). We observed higher levels of H-FABP and NF-L in older patients with mTBI. None of the biomarkers or their combinations was able to distinguish CT-positive (n=36) or CT-negative (n=58) patients with mTBI from controls.
CONCLUSIONS: S100B, H-FABP, NF-L and IL-10 levels in patients with mTBI were significantly lower than in patients with moTBI and sTBI but alone or in combination, were unable to distinguish patients with mTBI from orthopaedic controls. This suggests these biomarkers cannot be used alone to diagnose mTBI in trauma patients in the acute setting.
参考来源
- Koivikko P, Posti JP, Mohammadian M, et al. Potential of heart fatty-acid binding protein, neurofilament light, interleukin-10 and S100 calcium-binding protein B in the acute diagnostics and severity assessment of traumatic brain injury. Emerg Med J. 2021. PMID: 34916280. doi:10.1136/emermed-2020-209471
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。